123 related articles for article (PubMed ID: 8041153)
1. Precursor frequency analysis of bryostatin activated lymphocytes.
Fleming MD; Barrett SK; Bear HD
J Surg Res; 1994 Jul; 57(1):74-9. PubMed ID: 8041153
[TBL] [Abstract][Full Text] [Related]
2. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
[TBL] [Abstract][Full Text] [Related]
3. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
4. Bryostatin-1 enhances the maturation and antigen-presenting ability of murine and human dendritic cells.
Do Y; Hegde VL; Nagarkatti PS; Nagarkatti M
Cancer Res; 2004 Sep; 64(18):6756-65. PubMed ID: 15374994
[TBL] [Abstract][Full Text] [Related]
5. Activation of human T lymphocytes by bryostatin.
Hess AD; Silanskis MK; Esa AH; Pettit GR; May WS
J Immunol; 1988 Nov; 141(10):3263-9. PubMed ID: 3263418
[TBL] [Abstract][Full Text] [Related]
6. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins.
Trenn G; Pettit GR; Takayama H; Hu-Li J; Sitkovsky MV
J Immunol; 1988 Jan; 140(2):433-9. PubMed ID: 3257237
[TBL] [Abstract][Full Text] [Related]
8. Activation of nonspecific killer cells by interleukin 2-containing supernatants.
Teh HS; Yu M
J Immunol; 1983 Oct; 131(4):1827-33. PubMed ID: 6194216
[TBL] [Abstract][Full Text] [Related]
9. gamma-Interferon plays a key role in T-cell-induced tumor regression.
Tuttle TM; McCrady CW; Inge TH; Salour M; Bear HD
Cancer Res; 1993 Feb; 53(4):833-9. PubMed ID: 8428364
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C.
Isakov N; Galron D; Mustelin T; Pettit GR; Altman A
J Immunol; 1993 Feb; 150(4):1195-204. PubMed ID: 8432975
[TBL] [Abstract][Full Text] [Related]
11. Bryostatin-I: a dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine.
Yan W; Chen WC; Liu Z; Huang L
Cytokine; 2010 Dec; 52(3):238-44. PubMed ID: 20869878
[TBL] [Abstract][Full Text] [Related]
12. Effects of the protein kinase C stimulant bryostatin 1 on the proliferation and colony formation of irradiated human T-lymphocytes.
Sung SJ; Lin PS; Schmidt-Ullrich R; Hall CE; Walters JA; McCrady C; Grant S
Int J Radiat Biol; 1994 Dec; 66(6):775-83. PubMed ID: 7814976
[TBL] [Abstract][Full Text] [Related]
13. Stimulator cell requirements for allospecific T cell subsets: specialized accessory cells are required to activate helper but not cytolytic T lymphocyte precursors.
Czitrom AA; Sunshine GH; Reme T; Ceredig R; Glasebrook AL; Kelso A; MacDonald HR
J Immunol; 1983 Feb; 130(2):546-50. PubMed ID: 6600241
[TBL] [Abstract][Full Text] [Related]
14. The cytolytic T lymphocyte response to the murine cytomegalovirus. I. Distinct maturation stages of cytolytic T lymphocytes constitute the cellular immune response during acute infection of mice with the murine cytomegalovirus.
Reddehase MJ; Keil GM; Koszinowski UH
J Immunol; 1984 Jan; 132(1):482-9. PubMed ID: 6317749
[TBL] [Abstract][Full Text] [Related]
15. Phorbol dibutyrate and ionomycin improve murine effector cell cytotoxicity.
Hamby LS; Freeman JW; McGrath PC
J Surg Res; 1993 Feb; 54(2):115-21. PubMed ID: 8479168
[TBL] [Abstract][Full Text] [Related]
16. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
[TBL] [Abstract][Full Text] [Related]
17. Limiting dilution analysis of alloreactive cytotoxic precursor cells in aging mice.
Nordin AA; Collins GD
J Immunol; 1983 Nov; 131(5):2215-8. PubMed ID: 6226737
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
[TBL] [Abstract][Full Text] [Related]
19. Early loss of precursors of CTL and IL 2-producing cells in the development of neonatal tolerance to alloantigens.
Carnaud C; Ishizaka ST; Stutman O
J Immunol; 1984 Jul; 133(1):45-51. PubMed ID: 6233373
[TBL] [Abstract][Full Text] [Related]
20. Bryostatin 1 acts synergistically with interleukin-1 alpha to induce secretion of G-CSF and other cytokines from marrow stromal cells.
Lilly M; Vo K; Le T; Takahashi G
Exp Hematol; 1996 Apr; 24(5):613-21. PubMed ID: 8605966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
